Beta-blockers for the treatment of arrhythmias: Bisoprolol – a systematic review - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Annales Pharmaceutiques Françaises Année : 2022

Beta-blockers for the treatment of arrhythmias: Bisoprolol – a systematic review

Bêtabloquants pour le traitement des arythmies : bisoprolol – une revue systématique

L. Muresan
  • Fonction : Auteur correspondant
G. Cismaru
  • Fonction : Auteur
C. Muresan
  • Fonction : Auteur
R. Rosu
  • Fonction : Auteur
G. Gusetu
  • Fonction : Auteur
M. Puiu
  • Fonction : Auteur
R Mada
  • Fonction : Auteur

Résumé

Objectives: Beta-blockers have long been successfully used for the treatment of both supraventricular and ventricular arrhythmias. However, differences exist between their chemical structure, pharmacokinetic and pharmacodynamic properties (absorption, bioavailability, metabolism, hydrophilic or lipophilic character, selective or non-selective nature, the presence or absence of intrinsic sympathomimetic activity), which may confer different antiarrhythmic properties to different beta-blockers. The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and ventricular arrhythmias. Material and methods: Using the keywords “bisoprolol” and “arrhythmias” or “atrial fibrillation” or “ventricular tachycardia” or “premature ventricular complexes” or “ventricular fibrillation”, the Medline database was searched for articles in English or French until April 2020 assessing the role of bisoprolol in the treatment of arrhythmias. Data was then analyzed according to the type of arrhythmia treated and the quality of evidence using the GRADE approach. Results: A total of 325 studies were identified, of which 28 were considered relevant to the current topic. Among these studies, 19 assessed the role of bisoprolol for the treatment of supraventricular arrhythmias, 8 its role in treating ventricular arrhythmias and 1 its role in supraventricular and ventricular arrhythmias. The quality of evidence varied from low (7 studies) to high (5 studies). Conclusion: Current evidence exists supporting the use of bisoprolol for the treatment of supraventricular arrhythmias, especially for rate control during atrial fibrillation. Evidence also exists for its efficacy in the treatment of ventricular arrhythmias, both in primary and in secondary prevention.
Fichier principal
Vignette du fichier
Muresan et al-2022-Beta blockers for the treatment of arrhythmias.pdf (569.26 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03719705 , version 1 (19-07-2022)

Identifiants

Citer

L. Muresan, G. Cismaru, C. Muresan, R. Rosu, G. Gusetu, et al.. Beta-blockers for the treatment of arrhythmias: Bisoprolol – a systematic review. Annales Pharmaceutiques Françaises, 2022, 80 (5), pp.617-634. ⟨10.1016/j.pharma.2022.01.007⟩. ⟨hal-03719705⟩
916 Consultations
1276 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More